Information  X 
Enter a valid email address

Positive results for Lipoxen's ImuXen

By BFN News | 03:56 PM | Wednesday 28 April, 2010

Bio-pharmaceutical firm Lipoxen has received positive results for two of its ImuXen proprietary candidates - one as an influenza vaccine and the other as a malaria vaccine. Lipoxen's proprietary ImuXen technology is based on the use of natural substances found in the human body (lipids) to entrap the active ingredients (usually antigens) within liposomes to ensure their direct delivery to the appropriate cells of the immune system. It says this enhances the effectiveness of vaccines by generating strong and broadly based immune responses. Lipoxen chief executive Scott Maguire said: "I am further encouraged that one of our leading technology platforms has again demonstrated its potential to underpin a new generation of vaccine products with enhanced performance characteristics. "Along with increased efficacy, Lipoxen's refrigeration-free vaccines have the potential to solve yet another material issue in modern vaccines." Story provided by Business Financial Newswire

a d v e r t i s e m e n t